DoD Peer Reviewed Orthopaedic, Clinical Translational Research Award | W81XWH 22 PRORP CTRA

Opportunity Information: Apply for W81XWH 22 PRORP CTRA

The DoD Peer Reviewed Orthopaedic, Clinical Translational Research Award (CTRA) is a funding opportunity under the Department of Defense Congressionally Directed Medical Research Programs (CDMRP) Peer Reviewed Orthopaedic Research Program (PRORP). It is built around a straightforward military readiness problem: musculoskeletal and orthopaedic injuries are extremely common in both combat and non-combat settings and can delay or prevent return to duty, work, and normal activity. The announcement highlights that extremity battle wounds represent about half of the injuries captured in the Joint Theatre Trauma Registry, while training injuries, sports and leisure injuries, and complications from prior injuries also create a major readiness burden. The overarching intent is to support clinical research that improves early stabilization, treatment, rehabilitation, and overall outcomes, with an emphasis on reducing complications, morbidity, and limb loss by getting effective orthopaedic care closer to the point of injury and into practical clinical use.

This CTRA mechanism is designed specifically for clinical translational work, meaning it supports studies that move promising techniques, interventions, and care approaches into real patient settings. The program is looking for high-impact and/or new or emerging clinical research that can realistically change clinical practice, either in the near term (how injuries are evaluated and treated now) or long term (how care is standardized, optimized, and guided by evidence). A key theme is producing results that can shape evidence-based guidelines for diagnosing, treating, rehabilitating, and preventing orthopaedic injuries in military populations, Veterans, and civilians. The opportunity also emphasizes patient-centered outcomes such as health, functional ability, and quality of life, not just narrow clinical endpoints.

One of the practical distinctions the announcement makes is how the CTRA differs from the PRORP Clinical Trial Award (CTA). The CTA is limited strictly to clinical trials, while the CTRA is broader and can fund clinical research that may or may not include a clinical trial. Under the CTRA, interventional clinical studies are allowed, and limited retrospective analysis can be included to support the work. However, purely retrospective studies or projects that are essentially database-mining efforts are not permitted. Small pilot clinical trials involving human participants are explicitly allowed, which signals that the mechanism can support early-stage or proof-of-concept clinical testing when a full-scale randomized controlled trial may be premature.

The program is very clear about what it will not support: animal research is not allowed under this award. Applications must be clinical research as defined by CDMRP, including patient-oriented research with direct interaction with human subjects (or identifiable human-origin materials), epidemiologic and behavioral studies, and outcomes and health services research. The notice also clarifies that studies qualifying for IRB Exemption 4, meaning research using existing, de-identified specimens or publicly available de-identified data, are not considered CDMRP-defined clinical research for this mechanism. In other words, the award is meant for real clinical research with meaningful connection to patient care rather than solely secondary analysis of anonymous datasets.

Several core application expectations are spelled out. Preliminary data are required, and they need to be relevant to the proposed clinical study, which raises the bar for feasibility and readiness. Applicants must also demonstrate access to an appropriate study population and show a credible accrual plan, including how recruitment targets will be met and how women and minority participants will be included in a way that fits the study objectives. If the project involves a drug, device, or other intervention materials, the application must document availability and access for the full proposed study period. The program also expects a capable clinical research team and environment, including expertise in statistics, data management, and any relevant FDA regulatory pathways. For multi-step clinical research or any study resembling a trial, the announcement strongly signals the need for operational infrastructure, such as a study coordinator who can drive IRB submissions, manage regulatory steps, coordinate multi-site activities, and keep recruitment and protocol execution on track.

The funding notice places heavy emphasis on rigor in statistical and data practices. Applications are expected to include a clear statistical analysis plan, a power analysis tied to the study objectives and sample size assumptions, and a data management plan that protects data integrity. If the work is FDA-regulated, the study must use a database compliant with 21 CFR Part 11 and align with applicable data standards. For projects involving investigational drugs or devices, the opportunity outlines potential FDA requirements: an Investigational New Drug (IND) application under 21 CFR 312 may be needed for unapproved drug uses, and an Investigational Device Exemption (IDE) under 21 CFR 812 may be needed for investigational devices (with the possibility of abbreviated IDE pathways depending on device risk and use). If an IND, IDE, or international regulatory submission is required, it must be submitted within 12 months of the award date, and the government reserves the right to withdraw funding if required submissions are not made on time. For international clinical trial sites involving investigational products, submissions to host-country regulators may also be required within that same 12-month window.

If a proposed project includes a clinical trial as defined by prospective assignment of human subjects to an intervention to evaluate health-related outcomes, the award carries standard federal transparency requirements. Funded clinical trials must be registered on ClinicalTrials.gov before the study begins, and the informed consent form used for enrollment must be posted on a publicly available federal website in line with requirements described in 32 CFR 219. These expectations reinforce that the program is oriented toward accountable, publicly trackable clinical research with clear human-subject protections.

While the program is rooted in military relevance, it does not strictly require that all participants be active-duty Service Members or Veterans. Instead, every application must clearly explain why the project matters to military and/or Veteran populations affected by orthopaedic injury. Including active-duty military or Veteran participants is encouraged but not mandatory, and collaboration with military and Department of Veterans Affairs researchers or clinicians is also encouraged, presumably because it can improve relevance, recruitment feasibility, and pathways to implementation in military or VA care settings.

From an administrative and funding standpoint, awards are made as assistance agreements, meaning the government is supporting a public purpose rather than buying a service for direct government use. The mechanism can be issued as either a grant or a cooperative agreement, depending on the expected level of DoD involvement during performance. If substantial involvement is anticipated (for example, collaboration or participation in aspects of the research), it will be structured as a cooperative agreement; if not, it will be a standard grant. For FY22, the anticipated total cost cap per award is up to $1.5 million for the full period of performance. The program planned to allocate about $6.0 million total to fund roughly four awards. The opportunity information lists the administering agency as the Department of Defense, Department of the Army, USAMRAA, with CFDA number 12.420, and eligibility described as unrestricted (open broadly to entity types, subject to any additional clarifications in the full announcement). Key dates included a posting in April 2022 and an application deadline in September 2022, with awards expected no later than September 30, 2023, and FY22 funds anticipated to remain available for obligation and use consistent with federal fiscal rules through September 30, 2028.

Overall, the CTRA is aimed at well-justified, data-supported clinical studies that are far enough along to be feasible in human populations, but flexible enough to include emerging interventions, pilot clinical trials, and translational clinical work that can credibly shift orthopaedic care and rehabilitation practices. The strongest proposals under this mechanism are likely to be those that demonstrate real-world clinical applicability, a realistic recruitment and operations plan, regulatory readiness when applicable, and a clear line of sight to improving decision-making and outcomes for military, Veteran, and civilian patients dealing with serious musculoskeletal injuries.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed Orthopaedic, Clinical Translational Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 08, 2022.
• Applicants must submit their applications by Sep 13, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 PRORP CTRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: